The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: Kinetic and microscopic studies

Blood

Volumn 117, Issue 2, 2011, Pages 661-668

  Longstaff, Colin ^a   Thelwell, Craig ^a   Williams, Stella C ^a   Silva, Marta M C G ^a   Szabó, László ^b   Kolev, Krasimir ^c  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b CHEMICAL RESEARCH CENTER   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BINDING KINETICS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FIBRINOLYSIS; FLUORESCENCE; HUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; SCANNING ELECTRON MICROSCOPY; WILD TYPE;

EID: 78751560568     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-290338     Document Type: Article

References (43)

1. Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem. 2008;6(3):161-180.
2. Carr ME Jr, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis. 1995;6(6):567-573.
3. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992;267(34):24259-24263.
4. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol. 2000;20(5):1354-1361. (Pubitemid 30262939)
5. Kolev K, Tenekedjiev K, Komorowicz E, Machovich R. Functional evaluation of the structural features of proteases and their substrate in fibrin surface degradation. J Biol Chem. 1997;272(21):13666-13675. (Pubitemid 27224800)
6. Meh DA, Mosesson MW, DiOrio JP, et al. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis. Blood Coagul Fibrinolysis. 2001;12(8):627-637.
7. Pandi L, Kollman JM, Lopez-Lira F, Burrows JM, Riley M, Doolittle RF. Two families of synthetic peptides that enhance fibrin turbidity and delay fibrinolysis by different mechanisms. Biochemistry. 2009;48(30):7201-7208.
8. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation. 1995;92(7):1883-1890.
9. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2567-2573.
10. Kim PY, Stewart RJ, Lipson SM, Nesheim ME. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. J Thromb Haemost. 2007;5(6):1250-1256.
11. Collet JP, Soria J, Mirshahi M, et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability. Hypofibrinolysis related to an abnormal clot structure. Blood. 1993;82(8):2462-2469.
12. Marchi R, Mirshahi SS, Soria C, et al. Thrombotic dysfibrinogenemia: fibrinogen "Caracas V" relation between very tight fibrin network and defective clot degradability. Thromb Res. 2000;99(2):187-193.
13. Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res. 2002;90(4):428-434. (Pubitemid 34633912)
14. Urano S, Metzger AR, Castellino FJ. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators. Proc Natl Acad Sci U S A. 1989;86(8):2568-2571.
15. van Zonneveld AJ, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin: inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J Biol Chem. 1986;261(30):14214-14218. (Pubitemid 17196329)
16. Verheijen JH, Caspers MP, Chang GT, de Munk GA, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J. 1986;5(13):3525-3530.
17. Bennett WF, Paoni NF, Keyt BA, et al. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem. 1991;266(8):5191-5201.
18. Wu JH, Diamond SL. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin: a mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen. J Clin Invest. 1995;95(6):2483-2490.
19. Longstaff C, Whitton C, Thelwell C, Belgrave D. An international collaborative study to investigate a proposed reference method for the determination of potency measurements of fibrinolytics in absolute units. J Thromb Haemost. 2007;5(2):412-414. (Pubitemid 46139468)
20. Whitton C, Sands D, Lee T, Chang A, Longstaff C. A reunification of the US ("NIH") and International Unit into a single standard for Thrombin. Thromb Haemost. 2005;93(2):261-266. (Pubitemid 40253730)
21. Longstaff C, Wong MY, Gaffney PJ. An international collaborative study to investigate standardisation of hirudin potency. Thromb Haemost. 1993;69(5):430-435. (Pubitemid 23146435)
22. Longstaff C, Whitton C. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units. Thromb Haemost. 2004;2(8):1416-1421. (Pubitemid 40186140)
23. Sands D, Whitton C, Merton R, Longstaff C. A collaborative study to establish the 3rd international standard for tissue plasminogen activator. Thromb Haemost. 2002;88(2):294-297. (Pubitemid 34873712)
24. Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost. 2007;5(4):804-811. (Pubitemid 46563581)
25. Gebbink MF, Bouma B, Maas C, Bouma BN. Physiological responses to protein aggregates: fibrinolysis, coagulation and inflammation (new roles for old factors). FEBS Lett. 2009;583(16):2691-2699.
26. LeVine H 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274-284.
27. Kolev K, Longstaff C, Machovich R. Fibrinolysis at the fluid-solid interface of thrombi. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(4):341-355.
28. Weisel JW, Veklich Y, Collet JP, Francis CW. Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost. 1999;82(2):277-282.
29. Collet JP, Lesty C, Montalescot G, Weisel JW. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrinrich clots. J Biol Chem. 2003;278(24):21331-21335.
30. Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem. 1999;274(8):5201-5212.
31. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis: study with confocal microscopy. J Biol Chem. 1996;271(4):2133-2138.
32. Wu JH, Siddiqui K, Diamond SL. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. Thromb Haemost. 1994;72(1):105-112. (Pubitemid 24202304)
33. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost. 2003;89(3):409-419. (Pubitemid 36329229)
34. Doolittle RF. Searching for differences between fibrinogen and fibrin that affect the initiation of fibrinolysis. Cardiovasc Hematol Agents Med Chem. 2008;6(3):181-189.
35. Suenson E, Lutzen O, Thorsen S. Initial plasmindegradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem. 1984;140(3):513-522. (Pubitemid 14146534)
36. Tran-Thang C, Kruithof EK, Bachmann F. Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots. J Clin Invest. 1984;74(6):2009-2016. (Pubitemid 15197343)
37. Gebbink MF, Voest EE, Reijerkerk A. Do antiangiogenic protein fragments have amyloid properties? Blood. 2004;104(6):1601-1605. (Pubitemid 39202263)
38. Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink MF. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem. 2007;282(4):2229-2236.
39. Burton RA, Tsurupa G, Hantgan RR, Tjandra N, Medved L. NMR solution structure, stability, and interaction of the recombinant bovine fibrinogen alphaC-domain fragment. Biochemistry. 2007;46(29):8550-8560.
40. Cottrell BA, Doolittle RF. The amino acid sequence of a 27-residue peptide released from the alpha-chain carboxy-terminus during the plasmic digestion of human fibrinogen. Biochem Biophys Res Commun. 1976;71(3):754-761.
41. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A. 2006;103(4):903-908.
42. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariens RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood. 2010;115(19):3980-3988.
43. Gersh KC, Nagaswami C, Weisel JW. Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes. Thromb Haemost. 2009;102(6):1169-1175.